Acta Psychiatrica Scandinavica · 2004 · 17 citations · 26 references
MedicineNeurosciencePharmacologyNeuropharmacologyNeuropsychiatryPsychopharmacologyAddictionDopaminergic PharmacologyNicotine AddictionNicotine DependenceNicotine PharmacologyTobacco UseD2-like Dopamine ReceptorsDopamine D2-like ReceptorsDopamine Receptor SignalingHaloperidol PharmacologyNicotine Receptor PharmacologyPersistent SymptomsTardive Dyskinesia TreatmentTardive Dystonia
OBJECTIVE: Nicotine has a powerful preventive effect on neuroleptic-induced dopamine D2 receptor upregulation in the rat. The aim of this human positron emission tomography (PET) study was to compare upregulation in a smoker and a non-smoker, both of whom had received haloperidol for the same duration of time. METHOD: Two subjects who had been treated for 16 years with a constant dose of haloperidol were scanned after temporary haloperidol withdrawal, using [11C]-raclopride. RESULTS: The non-smoker, who had received a dose of 10 mg/day, showed a D2 upregulation of 98% and developed severe and persistent symptoms of tardive dyskinesia (TD) upon withdrawal. The chronic smoker, who had been treated with 40 mg/day, displayed a D2 upregulation of 71% and did not develop TD. CONCLUSION: These human observations agree with animal data which showed that nicotine can decrease neuroleptic-induced D2 receptor upregulation. This property of nicotine may play a protective role in movement disorders whose pathophysiology involves D2 receptor hypersensitivity.
26
A RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTS
G. M. Simpson, M. B., GH. B. et al. · Acta Psychiatrica Scandinavica · 1970 · 3.3K citations
Medicine, Pharmacology, Psychiatry +10